Medication-Related Osteonecrosis of the Jaws Bisphosphonates, Denosumab, and New Agents
Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody...
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2015, 2015
|
| Edition: | 1st ed. 2015 |
| Subjects: | |
| Online Access: | |
| Collection: | Springer eBooks 2005- - Collection details see MPG.ReNa |
Table of Contents:
- Pharmacology of Antiresorptive Drugs
- The Role of Antiresorptive Drugs in the Treatment of Osteoporosis
- The Role of Antiresorptive Drugs in the Treatment of Skeletal Manifestations of Malignant Diseases
- Clinical Features, Localization, Definition and Staging of the Disease
- Radiological Findings / Imaging
- General Characteristics and Risk Factors for BRONJ
- Epidemiology
- Histopathology of BRONJ
- Prevention of Osteonecrosis and Dentoalveolar Surgery Under Treatment With Antiresorptive Drugs
- Bisphosphonates and Dental Implants
- Treatment of BRONJ
- Local and Microvascular Flaps in ONJ-Treatment
- Rehabilitation of Patients After BRONJ
- Adjuvant Treatment Strategies
- Microbiology and Antibiotics
- Animal Models of ONJ
- ONJ Under Denosumab and Other New Drugs
- Possible Use of Antiresorptive Drugs in OMS
- Dental Treatment Under BPs and After BRONJ
- Dental Rehabilitation Under Bisphosphonates and After BRONJ
- History of ONJ.